Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma: early-phase trial registry
167 of 441 indexed Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11 of 28,707 conditions by registered trial count.
441 US clinical trials · 167 currently recruiting · #11 of 28,707 conditions by registered trial count
Multiple Myeloma: 441 US clinical trials tracked, 167 recruiting.
Multiple Myeloma is the subject of 441 registered US clinical trials on ClinicalTrials.gov, 167 of them currently open to new participants. 52 are in Phase 3-4 (later-stage) and 298 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition multiple-myeloma
OPEN 167 | RECR 38% | LATE 52 | EARLY 298 | RANK #11 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Multiple Sclerosis (38% recruiting · 317 trials)
Multiple Myeloma lists 167 open slots (38% of 441 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma recruits in line with its size-band peers.
167 of 441 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 441 trials (7.7%). 154 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Myeloma enrolment sits around 65 participants.
Median target enrolment is 65 among the 439 trials that report a genuine target (sentinel values excluded). 262 of those (59.7%) plan for fewer than 100 participants.
-
Multiple Myeloma research is mostly interventional.
386 interventional and 55 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
441 total, page 2 of 9
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT06679829
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT05650632
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Memorial Sloan Kettering Cancer Center
NCT06055894
Sleep Apnea in Patients With MGUS and MM
Michael Tomasson
NCT04114084
The Ambient Light Multiple Myeloma Study
Icahn School of Medicine at Mount Sinai
NCT05737732
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda
NCT06980480
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Augusta University
NCT06588413
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
City of Hope Medical Center
NCT06052826
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT07266441
Study of CAR-T Therapy in Older Patients
Memorial Sloan Kettering Cancer Center
NCT04300998
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
GlaxoSmithKline
NCT05714839
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Regeneron Pharmaceuticals
NCT05828511
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT06121843
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
NCT06896916
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Oncotherapeutics
NCT03110822
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
NCT06953960
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics
NCT06119685
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics
NCT05651932
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
University of Utah
NCT05405387
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
University of Miami
NCT06997081
VitD3 Supplementation in Patients With Multiple Myeloma
Amany Keruakous, MD, MS.
NCT05846880
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Mayo Clinic
NCT06042725
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Memorial Sloan Kettering Cancer Center
NCT06976476
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations
NCT05972135
Precision Medicine Study
Icahn School of Medicine at Mount Sinai
NCT06338150
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Pack Health
NCT05956457
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical
NCT04771572
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
C4 Therapeutics
NCT07284758
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Thomas Jefferson University
NCT07188090
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Emory University
NCT07101445
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Pfizer
NCT05675449
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Massachusetts General Hospital
NCT05646576
Personalized Autologous Transplant for Multiple Myeloma
Emory University
NCT04483206
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
University of Nebraska
NCT04898790
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Pfizer
NCT06215118
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago
NCT05789303
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Mayo Clinic
NCT06630104
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Pfizer
NCT06057402
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05092451
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Heidelberg Pharma
NCT04879043
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
NCT06179888
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
NCT04822337
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
NCT05199311
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
NCT06483100
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT07099391
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
NCT06988488
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
NCT05776979
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Janssen Research & Development
NCT07149857
18F-Fluciclovine PET/CT in Multiple Myeloma
National Cancer Institute (NCI)
NCT06103838
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
NCT06107738
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 142 |
| Phase 3 | 45 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Myeloma page
441 registered trials, 167 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 167 Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Myeloma condition card totals 441 registered trials; most-linked intervention Dexamethasone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.